Carl H. June, MD, FAACR
Richard W. Vague Professor in ImmunotherapyDepartment of Pathology and Laboratory Medicine
University of Pennsylvania Perelman School of Medicine
Dr. June is the Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. In 2011, his research team published findings detailing a new therapy in which patients with refractory and relapsed chronic lymphocytic leukemia were treated with genetically engineered versions of their own T cells. The treatment has also now also been used with promising results to treat children with refractory acute lymphoblastic leukemia, and adults with refractory lymphoma. CTL019, the CAR T cell developed in the June laboratory was the first gene therapy to be approved by the US FDA in August 2017. Dr. June has published more than 400 manuscripts and is the recipient of numerous prizes and honors, including the Karnofsky Prize from the American Society of Clinical Oncology, and a lifetime achievement award from the Leukemia and Lymphoma Society.